ethyl 4-hydroxy-2-methylbutanedioate | 80566-57-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 4-hydroxy-2-methylbutanedioate
• 英文别名: 4-hydroxy-2-methylbutyric acid ethyl ester；ethyl 4-hydroxy-2-methylbutanoate；4-Hydroxy-2-methyl-butyric acid ethyl ester
• CAS: 80566-57-0
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: YARDKGCSTRNORB-UHFFFAOYSA-N

物化性质

• 沸点：
  216.5±23.0 °C(Predicted)
• 密度：
  1.005±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-hydroxy-2-methylbutanedioate 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 以100%的产率得到α-甲基-γ-丁内酯
  参考文献：
  名称：

  A New Preparation of Cyclopropanone Hemiketals by Reductive Coupling of Terminal Olefins with Ethylene Carbonate

  摘要：

  DOI：

  10.1021/jo960856f
• 作为产物：
  描述：

  4-甲基-2-酮戊二酸 在 baker's yeast 、 水 、 对甲苯磺酸 作用下， 以 苯 为溶剂， 反应 72.0h， 生成 ethyl 4-hydroxy-2-methylbutanedioate
  参考文献：
  名称：

  Chemoenzymatic synthesis of optically active 4-methyl-tetrahydro-5-oxo-2-furancarboxylic acids and esters

  摘要：

  Enantiomerically pure 4-methyl-tetrahydro-5-oxo-2-furancarboxylic acids and esters are prepared by enzymatic resolution of the chiral racemic esters. Their stereochemistry as well as their absolute configurations have been established by chemical correlation. The influence of the alkoxycarbonyl group at C-2 and that of the methyl group at C-4 on the sign of the Cotton effect in their CD spectra have been investigated. Formation of enantiomerically pure hydroxydiesters, precursors of the above-mentioned gamma-lactones, by baker's yeast reduction of the corresponding ketodiesters was unsatisfactory. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(00)00057-4

文献信息

• Asymmetric Reductive Carbocyclization Using Engineered Ene Reductases
  作者：Kathrin Heckenbichler、Anna Schweiger、Lea Alexandra Brandner、Alexandra Binter、Marina Toplak、Peter Macheroux、Karl Gruber、Rolf Breinbauer

  DOI：10.1002/anie.201802962

  日期：2018.6.11

  bearing an electron‐withdrawing group, for example, a carbonyl group. This asymmetric reduction has been exploited for biocatalysis. Going beyond its canonical function, we show that members of this enzyme family can also catalyze the formation of C−C bonds. α,β‐Unsaturated aldehydes and ketones containing an additional electrophilic group undergo reductive cyclization. Mechanistically, the two‐electron‐reduced

  来自老黄酶 (OYE) 家族的烯还原酶可还原带有吸电子基团（例如羰基）的 α,β-不饱和化合物中的 C=C 双键。这种不对称还原已被用于生物催化。除了其典型功能之外，我们还发现该酶家族的成员还可以催化 C−C 键的形成。含有额外亲电基团的 α,β-不饱和醛和酮会发生还原环化。从机制上讲，双电子还原酶辅因子 FMN 传递氢化物以生成烯醇化物中间体，该中间体与内部亲电子试剂发生反应。用非质子 Phe 或 Trp 单位点取代关键的 Tyr 残基有利于环化反应而不是自然还原反应。新的转化使得对映选择性合成手性环丙烷的效率高达 >99% 。
• BICYCLIC PYRAZOLE DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1659123A1

  公开（公告）日：2006-05-24

  A compound represented by the following formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of either. These are compounds having high DPP-IV inhibitory activity and improved in safety, nontoxicity, etc. (I) [In the formula, R1 represents hydrogen, optionally substituted alkyl, etc.; the solid line and dotted line between A1 and A2 indicate a double bond (A1=A2), etc.; A1 represents a group represented by the formula C(R2), etc.; A2 represents a group represented by the formula C(R4), etc.; R2 represents hydrogen, optionally substituted alkyl, etc.; R4 represents hydrogen, optionally substituted alkyl, etc.; R6 represents hydrogen, optionally substituted aryl, etc.; and -Y represents, e.g.; a group represented by the formula (A): (A) (wherein ml is 0, 1, 2, or 3; and R7 is absent, or one or two R7's are present and each independently represents optionally substituted alkyl, etc.).]

  以下式(I)表示的化合物、前药或药用可接受的盐。这些化合物具有高DPP-IV抑制活性，并且在安全性、非毒性等方面进行了改进。(I) [在公式中，R1代表氢，可选地取代烷基等；A1和A2之间的实线和虚线表示双键(A1=A2)等；A1代表由公式C(R2)等表示的基团；A2代表由公式C(R4)等表示的基团；R2代表氢，可选地取代烷基等；R4代表氢，可选地取代烷基等；R6代表氢，可选地取代芳基等；-Y代表例如；由公式(A)表示的基团：(A)(其中ml为0、1、2或3；R7缺失，或存在一个或两个R7，每个独立地代表可选地取代烷基等)。]
• [EN] CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDES CYCLIQUES À SUBSTITUTION PHOSPHATE ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2017223020A1

  公开（公告）日：2017-12-28

  The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Q, V, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Derivative, and methods of using the Cyclic Phosphate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

  本发明涉及公式（I）的环磷酸酯取代核苷衍生物及其药用可接受的盐，其中A、B、Q、V、R1、R2和R3如本文所定义。本发明还涉及包含环磷酸酯取代核苷衍生物的组合物，以及使用这些环磷酸酯取代核苷衍生物治疗或预防患者HCV感染的方法。
• NOVEL CONDENSED IMIDAZOLE DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1690863A1

  公开（公告）日：2006-08-16

  Disclosed is a compound represented by the formula (1) below which has a high DPP-IV inhibitory activity and is improved in safety, toxicity and the like. Also disclosed is a prodrug of such a compound and pharmaceutically acceptable salts of them. (In the formula, R1 represents a hydrogen atom, an optionally substituted alkyl group or the like; R2 and R3 independently represent a hydrogen atom, an optionally substituted alkyl group or the like; R4 and R5 independently represent a hydrogen atom, an optionally substituted alkyl group or the like: R6 represents a hydrogen atom, an optionally substituted aryl group or the like; and -Y-NH2, represents a group represented by the following formula (A): (wherein m is 0, 1 or 2; and R7 may not exist or one or two R7 may exist and independently represent an optionally substituted alkyl group or the like) or the like.]

  揭示了一种化合物，其化学式如下（1），具有较高的DPP-IV抑制活性，并在安全性、毒性等方面得到改善。还披露了这种化合物的前药和其药用可接受的盐。（在该式中，R1代表氢原子、可选择取代的烷基或类似物；R2和R3独立代表氢原子、可选择取代的烷基或类似物；R4和R5独立代表氢原子、可选择取代的烷基或类似物；R6代表氢原子、可选择取代的芳基或类似物；-Y-NH2代表由以下式（A）表示的基团：（其中m为0、1或2；R7可能不存在，或一个或两个R7可以存在且独立代表可选择取代的烷基或类似物）或类似物。）
• [EN] BIARYL DERIVATIVES AS GPR120 AGONISTS<br/>[FR] DÉRIVÉS DE BIARYLE EN TANT QU'AGONISTES DE GPR120
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2014209034A1

  公开（公告）日：2014-12-31

  The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

  本发明涉及公式1的联苯衍生物，一种制备该联苯衍生物的方法，包含该联苯衍生物的药物组合物以及其用途。根据本发明的公式1的联苯衍生物促进胃肠道中GLP-1的形成，并由于巨噬细胞、脂肪细胞等中的抗炎作用改善肝脏或肌肉中的胰岛素抵抗，因此可有效用于预防或治疗糖尿病、糖尿病并发症、肥胖、非酒精性脂肪肝、脂肪性肝炎、骨质疏松症或炎症。